thigh-length CES, and in 36 (27.3%) of those randomized to the below-knee group (p=0.017), and led to premature discontinuation of their use in 29 (21.5%) and 18 (13.6%) patients, respectively. We conclude that thigh-length CES do not offer a better protection against PTS than below-knee CES and are less well tolerated (Clinical Trial number: NCT00426075).
Introduction
Compression elastic stockings (CES) have been shown to offer substantial protection against the development of the postthrombotic syndrome (PTS) in patients with proximal deep venous thrombosis (DVT) 1 . Although the precise mechanism by which stockings reduce the risk of the PTS is unknown, they are likely to counterbalance the effects of venous hypertension resulting from persistent venous obstruction and/or valve damage and assist the muscle pump function. [2] [3] [4] [5] The latest international guidelines recommend the use of CES in all patients with proximal DVT for at least two years. 6, 7 In two randomized studies in patients with proximal deep venous thrombosis, the use of below-knee CES for at least two years was associated with some 50% reduction in the incidence of the PTS compared to patients without CES. 8, 9 However, despite this large reduction, 25% of patients still develop post-thrombotic manifestations, which are severe in 2 to 5%.
In clinical practice, many physicians recommend the use of thigh-length CES over below knee CES, especially in patients with extensive proximal DVT, because of a perceived higher degree of protection against the development of the PTS. 4 In order to assess the potential benefit of thigh-length over below-knee CES for prevention of the PTS, we performed a multicenter randomized study in patients with a first episode of proximal DVT. In both study arms patients were encouraged to use their stockings for two years.
The Villalta scale was used for the classification of PTS. 
Methods

Study design and outcomes
This randomized clinical trial compared the efficacy of thigh-length CES with that of below-knee CES, given for two years, for prevention of the PTS in patients with a first episode of proximalvein thrombosis. The primary analysis concerned the 3-year cumulative incidence of the PTS. In addition, compliance to the assigned CES and their tolerability was assessed. Patients who passed the screen of inclusion and exclusion criteria were asked to participate in the study after receiving detailed written information about study hypotheses and procedures. Study patients had to give written informed consent to participate in the study in accordance with the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of each participating center. 
Patients
Anticoagulant treatment
Patients were treated with low-molecular-weight heparin, Patients were discharged with a letter for their family physician, indicating that they had accepted to participate in a randomized study on CES. Both patients and their family physicians were given a card with the telephone numbers of the thrombosis clinic.
Follow-up and assessment of recurrent thromboembolism
Patients were followed-up for up to three years. The study was stopped when the last recruited patient completed the 3-year study period.
Patients were asked to visit the study center at three and six months from the index event and then every six months. In the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 8 interval between scheduled visits, patients were asked to report to the study center if a deterioration of symptoms or signs occurred.
Patients who could not attend follow-up examinations at the study center were visited at home.
Patients were asked to return to the center if they developed symptoms suggestive of recurrent venous thromboembolism. The diagnosis of recurrent thromboembolic events was made as previously described. 11 For all patients who died during follow-up, the date and cause of death were retrieved.
Assessment of the post-thrombotic syndrome
Patients were instructed not to wear their stocking on the day of assessment and not to reveal their treatment allocation to the assessor. Each PTS assessment was done by study personnel aware of the side of the index venous thrombosis, but unaware of the treatment allocation and of the results of previous measurements. Only the side of the index venous thrombosis was considered for the development of the PTS.
The presence and severity of post-thrombotic signs and symptoms was assessed at predefined times (3, 6, 12, 24 and 36 months after the acute episode) using the Villalta scale. 10 Briefly, the presence of five leg symptoms (i.e., pain, cramps, heaviness, pruritus, and paresthesia) and six objective signs (i.e., pretibial edema, induration of the skin, hyperpigmentation, new venous ectasia, redness and pain during calf compression) was scored. For each item, a score of 0 up to 3 was assigned using the contralateral An independent adjudication committee, whose members were not involved in the clinical assessments and who were unaware of treatment allocation, evaluated the scoring forms at the end of follow-up and classified the outcome status of the patients.
Compliance, adverse effects, and cointerventions
Patients were asked to document their use of the CES, the occurrence of side-effects, and cointerventions. For this purpose, they were instructed to report every day on a booklet the duration they wore the assigned stocking, use of not permitted stockings, occurrence of possible adverse effects (such as itching, erythema, or other forms of allergic reaction), use of analgesic or antiinflammatory drugs (including aspirin), and to bring it to the study physicians on the day of visits. Compliance was defined as satisfactory if stockings were reportedly used for at least 70% of daytime. 
The chi-square test was used for comparison of compliance and tolerability. P-values lower than 0.05 were regarded as statistically significant.
All calculations were performed with SPSS version 18.0 (SPSS Inc., Chicago, IL). During the study period, 11 patients were lost to follow-up (8 in the thigh-length and 3 in the below-knee study group), and 31 died (14 in the thigh-length, and 17 in the below-knee study group, respectively). In none of the patients death was attributed to PE.
Results
Patients
The average duration of follow-up was 32.5 + 8.3 months in the thigh-length, and 32.6 + 8.2 months in the below-knee group.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From During the study period, 12 patients in each group (8.9% in the thigh-length and 9.0% in the below-knee group) developed non-fatal recurrent VTE, with the involvement of the initially affected leg in 6 and 9 patients, respectively. 
Post-thrombotic syndrome
Discussion
Despite appropriate anticoagulant therapy, 25 to 50% of patients develop long-term post-thrombotic sequelae after an episode of DVT. 12 Established PTS remains a significant cause of chronic illness, with considerable socio-economic consequences for both patients and health care providers. 13, 14 Among factors that have been found to be associated with an increased risk of PTS are proximal location of the initial thrombosis -especially the iliofemoral location, the development of recurrent ipsilateral DVT and the inadequacy of oral anticoagulant therapy. 9, 15, 16 The incidence of the PTS is reduced by use of graduated compression stockings. 1, 8, 9 However, uncertainty remains about the choice of the most suitable type of stocking, as in proper studies on the value of elastic stockings for prevention of PTS only below-knee stockings were used. 8, 9 Thigh-length CES are generally perceived as more effective, especially in patients with the most proximal involvement of the venous system, 4 but are more expensive and may not be as practical and tolerable as the below-knee CES. In order to assess the relative role of these two types of garments, we decided to conduct a head-to-head comparison.
We failed to show any advantage of the thigh-length over the The slight difference in the proportion of patients allocated to below-knee stockings who developed PTS between this (35%) and our previous investigation (25%) 9 most likely reflects the difference in patients age. Age was indeed found to be an important predictor of PTS development, 9,17 and in the current investigation patients age (mean, 67 to 69) was substantially higher than that (mean, 60
to 63) recorded in the previous one. Interestingly enough, in both studies the rate of severe PTS was consistently low.
Not unexpectedly, the thigh-length stockings were significantly less well tolerated. Indeed, a higher proportion of patients allocated to thigh-length CES developed stockings-related side-effects (40.7 vs 27.3%), which led to premature discontinuation in 21.5 and 13.6%, respectively. In addition, only 67% of the patients allocated to thigh-length CES used their garments for at least 70% of daytime, as compared to 83% of patients allocated to the belowknee CES.
Some methodological issues require comment. Only patients with proximal DVT who were admitted to hospital departments were eligible for the current investigation, hence not necessarily can the In addition, a blinded adjudication committee evaluated the scoring forms at the end of follow-up. Finally, the length of CES use (two years) was decided in agreement with the latest ACCP guidelines, 6 and the diagnosis of the PTS was based on a validated scale, which has a good correspondence with patient's perception of quality of life and has a high reproducibility. 17 Below-knee CES should be regarded as the stockings of choice for prevention of the PTS in patients with proximal DVT. Indeed, they have similar effectiveness as thigh-length stockings, while having a better tolerability and lower cost. Indeed, the belowknee garments that were used in this study are currently marketed in Europe at the price of approximately € 42 as compared to € 75 (that is, 56% less expensive) for the thigh-length ones.
Although a considerable proportion of patients wearing belowknee stockings still develop the PTS, the rate of severe sequelae is acceptably low. Whether aggressive treatment of the initial 
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